References
- Means JH . The use of radioactive iodine in the diagnosis and treatment of thyroid diseases. Bull. NY Acad. Med.24(5), 273–286 (1948).
- Thornton K , KimG, MaherVEet al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: US Food and Drug Administration drug approval summary. Clin. Cancer Res.18(14), 3722–3730 (2012).
- Brose MS , NuttingC, JarzabBet al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the Phase III DECISION trial. J. Clin. Oncol.31(Suppl.), Abstract 4 (2013).
- Harris PJ , BibleKC. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin. Investig. Drugs20(10), 1357–1375 (2011).
- Anderson RT , LinnehanJE, TongbramV, KeatingK, WirthLJ. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid23(4), 392–407 (2013).
- Carhill AA , CabanillasME, JimenezCet al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J. Clin. Endocrinol. Metab.98(1), 31–42 (2013).
- Smallridge RC , AinKB, AsaSLet al. American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid22(11), 1104–1139 (2012).
- American Cancer Society . Cancer Facts and Figures 2013. American Cancer Society, GA, USA (2013).
- Al-Eid HS , ArtehSO. Cancer Incidence Report Saudi Arabia 2003, Kingdom of Saudi Arabia Ministry of Health National Cancer Registry.
- Aschebrook-Kilfoy B , SchechterRB, ShihYCet al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol. Biomarkers Prev.22(7), 1252–1259 (2013).
- Schutz FA , JeY, RichardsCJ, ChoueiriTK. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J. Clin. Oncol.30(8), 871–877 (2012).
- Ramsey S , BloughD, KirchhoffAet al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff. (Millwood)32(6), 1143–1152 (2013).
- “Health care systems: Getting more value for money” , OECD Economics Department Policy Notes, No. 2. Organization for Economic Cooperation and Development, Paris, France (2010).
- Buy Sorafenib . http://buysorafenib.com/.
- Leboulleux S , BastholtL, KrauseTet al. Randomized Phase 2 trials in DTC: vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, Phase 2 trial. Lancet Oncol.13(9), 897–905 (2012).
- Elisei R , SchlumbergerMJ, MüllerSPet al. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol.31(29), 3639–3646 (2013).
- Schlumberger M , JarzabB, EliseiRet al. Phase III randomized, double-blinded, placebo controlled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer – exploratory analyses of patient-reported outcomes. Presented at: 2013 Annual Meeting of the American Thyroid Association.San Juan, Puerto Rico, 16–20 October 2013.
- Experts in Chronic Myeloid Leukemia . The price of drugs in chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood121(22), 4439–4442 (2013).
- Chow CJ , HabermannEB, AbrahamAet al. Does enrollment in cancer trials improve survival? J. Am. Coll. Surg. 216(4), 774–780 (2013).
- Suvarna V . Phase IV of drug development. Perspect. Clin. Res.1(2), 57–60 (2010).
- Kesselheim AS . Using market-exclusivity incentives to promote pharmaceutical innovation. N. Engl. J. Med.363(19), 1855–1862 (2010).